Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment.
Garmendia I, Varthaman A, Marmier S, Angrini M, Matchoua I, Darbois-Delahousse A, Josseaume N, Foy PE, Roumenina LT, Naouar N, Meylan M, Sibéril S, Russick J, Joubert PE, Leroy K, Damotte D, Mansuet-Lupo A, Wislez M, Alifano M, Menger L, Garcia-Verdugo I, Sallenave JM, Lantz O, Petitprez F, Cremer I. Garmendia I, et al. Among authors: leroy k. Cancer Immunol Res. 2023 Apr 3;11(4):530-545. doi: 10.1158/2326-6066.CIR-22-0534. Cancer Immunol Res. 2023. PMID: 36883368
Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells.
Bennett Saidu NE, Bretagne M, Mansuet AL, Just PA, Leroy K, Cerles O, Chouzenoux S, Nicco C, Damotte D, Alifano M, Borghese B, Goldwasser F, Batteux F, Alexandre J. Bennett Saidu NE, et al. Among authors: leroy k. Oncotarget. 2018 Jan 10;9(10):9088-9099. doi: 10.18632/oncotarget.24144. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507676 Free PMC article.
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D. Biton J, et al. Among authors: leroy k. Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15. Clin Cancer Res. 2018. PMID: 29764856
[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A, Alifano M, Wislez M, Boulle G, Velut Y, Biton J, Cremer I, Goldwasser F, Leroy K, Damotte D. Lupo A, et al. Among authors: leroy k. Rev Pneumol Clin. 2018 Oct;74(5):339-350. doi: 10.1016/j.pneumo.2018.09.010. Epub 2018 Oct 15. Rev Pneumol Clin. 2018. PMID: 30337201 Review. French.
[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?].
Hamard C, Mignard X, Pecuchet N, Mathiot N, Blons H, Laurent-Puig P, Leroy K, Lupo A, Chapron J, Giraud F, Arrondeau J, Goldwasser F, Alifano M, Damotte D, Wislez M. Hamard C, et al. Among authors: leroy k. Rev Pneumol Clin. 2018 Oct;74(5):327-338. doi: 10.1016/j.pneumo.2018.09.013. Epub 2018 Oct 19. Rev Pneumol Clin. 2018. PMID: 30343945 Review. French.
Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options.
Tlemsani C, Leroy K, Gimenez-Roqueplo AP, Mansuet-Lupo A, Pasmant E, Larousserie F, Boudou-Rouquette P, Vidaud M, Cadranel J, Blons H, Goldwasser F, Laurent-Puig P. Tlemsani C, et al. Among authors: leroy k. J Med Genet. 2020 Feb;57(2):104-108. doi: 10.1136/jmedgenet-2018-105594. Epub 2018 Oct 23. J Med Genet. 2020. PMID: 30352869
NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.
Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E. Tlemsani C, et al. Among authors: leroy k. Cancer Med. 2019 Aug;8(9):4330-4337. doi: 10.1002/cam4.2175. Epub 2019 Jun 14. Cancer Med. 2019. PMID: 31199580 Free PMC article.
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Damotte D, Warren S, Arrondeau J, Boudou-Rouquette P, Mansuet-Lupo A, Biton J, Ouakrim H, Alifano M, Gervais C, Bellesoeur A, Kramkimel N, Tlemsani C, Burroni B, Duche A, Letourneur F, Si H, Halpin R, Creasy T, Herbst R, Ren X, Morel P, Cesano A, Goldwasser F, Leroy K. Damotte D, et al. Among authors: leroy k. J Transl Med. 2019 Nov 4;17(1):357. doi: 10.1186/s12967-019-2100-3. J Transl Med. 2019. PMID: 31684954 Free PMC article.
[SMARCA4-deficient thoracic tumors: A new entity].
Decroix E, Leroy K, Wislez M, Fournel L, Alifano M, Damotte D, Mansuet-Lupo A. Decroix E, et al. Among authors: leroy k. Bull Cancer. 2020 Jan;107(1):41-47. doi: 10.1016/j.bulcan.2019.12.001. Epub 2020 Jan 6. Bull Cancer. 2020. PMID: 31916995 Review. French.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Among authors: leroy k. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
210 results